NCT05647096View on ClinicalTrials.gov

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

May 5, 2027

Study Completion Date

May 28, 2027

Conditions

SepsisRespiratory Failure

Interventions

DEVICE

NucleoCapture device

100ml NucleoCapture selective DNA adsorber

Trial Locations (9)

Unknown

University of Bonn, Bonn

Technical University Dresden, Dresden

Hannover Medical School, Hannover

University of Zurich, Zurich

Queen Elizabeth Hospital Birmingham, Birmingham

Royal Infirmary of Edinburgh, Edinburgh

Liverpool University Hospital, Liverpool

Guy's and St Thomas' Hospital, London

University College London, London

All Listed Sponsors

collaborator

ISS AG

UNKNOWN

lead

Santersus AG

INDUSTRY

NCT05647096 - Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis | Biotech Hunter | Biotech Hunter